TOKYO, Dec. 6, 2024 — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that M3, Inc. (TOKYO PRIME: 2413), or an affiliated company within the M3 group, is investing in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a MEDIROM subsidiary. NFES Technologies Inc. is leading the Series A round, which values MEDIROM MOTHER Labs at JPY9 billion pre-money (approximately USD $59,000,000 as of December 1, 2024). Further details are available at [link removed for brevity].

Forward-Looking Statements Concerning MEDIROM

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements, which may include projections of MEDIROM’s operational results, financial position, strategies, market prospects, competitive standing, and growth potential, are often identified by words like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or similar expressions. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on these statements.

More information on these risks and other factors that could impact MEDIROM’s business, results, financial condition, and stock price is provided in MEDIROM’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” and “Operating and Financial Review and Prospects” sections of its most recent Form 20-F and subsequent filings, accessible on the SEC website at www.sec.gov. MEDIROM disclaims any obligation to update these forward-looking statements.

ABOUT M3, Inc.
M3 is a unique venture company providing a range of global services centered around its physician platform, m3.com.

M3, one of the first post-2000 companies in the Nikkei 225 Index, boasts a physician member panel of over 330,000 in Japan and over 6,500,000 globally, facilitating healthcare innovation and reform.

Tokyo Stock Exchange Prime Market (Securities code 2413)
1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN
Web

ABOUT MEDIROM MOTHER Labs Inc.
A MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) subsidiary, MEDIROM MOTHER Labs focuses on health technology. Key offerings include the “Specific Health Guidance Program” via the “Lav” health app and the development and sale of the 24/7 recharge-free MOTHER Bracelet smart tracker. MOTHER Labs leverages the MOTHER Bracelet’s features to provide customized health management solutions across various sectors, including healthcare, logistics, and manufacturing.

MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web 
Contact:

MEDIROM MOTHER Labs Inc.
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan

The MOTHER Bracelet is the world’s first* 24/7 recharge-free smart tracker. Utilizing innovative technology from a Silicon Valley company, it generates power from temperature differences between the body and the surrounding air. This eliminates data loss associated with charging. It tracks heart rate, calories burned, body surface temperature, steps, and sleep.
Official Website: 

“`